

# Porcine Animal Model of Ventilator-Associated Bacterial Pneumonia Caused by Pseudomonas aeruginosa or Acinetobacter baumannii


Andrew Phipps, DVM, PhD, DACVM

Contractor in support of the Biomedical Advanced Research and Development Authority

March 5<sup>th</sup>, 2020

**UNCLASSIFIED** 

#### **BARDA Nonclinical Division**





## **Application of Animal Models in Drug Development**

- …"When human efficacy studies are not ethical and field trials are not feasible"
- Well-understood disease mechanism and prevention/reduction by the product
- Action within animal model(s) should be predictive of human response
- Endpoints related to the desired benefit in humans
- PD/PK data for translation of an effective dose to humans



## Development of Large Animal Models for Antibacterial Drug Development

Obtain efficacy data from adequately characterized animal model(s)

- Could be supplemented with clinical data from patients with a variety of infections caused by *P. aeruginosa* in one or more descriptive studies
- There are currently no adequately characterized animal models for the indications being considered
- Unlike trials for biothreat agents, it is ethical to conduct human efficacy trials; however, feasibility of conducting such trials is the issue



### **Advantages of Porcine Model**

- Anatomical, physiological and biochemical similarities to humans
- Gross and microscopic anatomy of the porcine lung is similar to human lungs
- Similar array of innate immune function in the lungs
- Large size amenable to the use of equipment typically used for humans in critical care scenarios
- Previous VABP studies using swine have also demonstrated that they can be mechanically ventilated for 3-4 days after bacterial inoculation, which allows sufficient time for development of disease, initiation of therapy, and monitoring the response to therapy (LiBassi et al., 2014)



### **Study Plan**

 Create and characterize strains of ceftriaxone-resistant Acinetobacter baumannii and Pseudomonas aeruginosa

- Pilot to establish prolonged ventilation in the porcine model
  - Female Yorkshire-Landrace crossbred juvenile pigs
  - Anesthetized and ventilated for 96 hours
  - Antibiotic treatment to minimize spontaneous pneumonia
- Establish bronchoscopic challenge and dose ranging for each strain
- Characterize the natural history of VABP disease in the porcine model
  - Monitor disease development and progression
  - Establish euthanasia criteria
- Utilize the developed model to evaluate the efficacy of antibacterial drugs to which the strains are susceptible and resistant




## **Challenges and Considerations**

- Catheterization
  - Venous & arterial
  - Urinary
- Intubation
  - Endotracheal tube
  - Mechanical ventilation
- Maintenance & Support
  - Continuous rate infusion anesthesia
  - IV fluids
  - Vital sign monitoring
  - Hematology, clinical chemistry
- Euthanasia
  - Necropsy
  - Bacteriology



## **Positioning**

- Trendelenburg position at -15 degree angle relative to the horizontal plane
  - Ventral Recumbency
  - Restraints
  - Foam padding
- Pressure sores
  - Sternum
  - Hind limbs
  - Forelimbs





## **Monitoring**

- Heart rate
- Mean arterial pressure (MAP)
- Core body temperature
- SpO<sub>2</sub> (pulse oximeter)
- ECG
- Urine output
- Arterial blood gas
- Respiratory rate
- Spontaneous respiration rate


- Total minute volume
- End tidal CO<sub>2</sub>
- FiO<sub>2</sub>
- P<sub>aw</sub> plateau
- Peak inspiratory pressure
- Compliance
- Resistance
- PO<sub>2</sub>/FiO<sub>2</sub> (calculated)
- ETT Cuff Pressure


- Tracheal secretion quantity (estimated)
- Tracheal secretion quality
- Hematology (every 24 hours)
- Clinical chemistry (every 24 hours)
- Porcine CRP
- Porcine procalcitonin



#### Ceftriaxone

- Intravenous dose of 50 mg/kg q12h
- 30 minute infusion
- Start within two hours of mechanical ventilation





Note: If we assume that the unbound fraction is between 50-60%, then a dose of 50 mg/kg q12h should provide coverage for organisms with a ceftriaxone MIC  $\leq$  2 ug/mL



## **Bacteriology**

- Blood culture at time of euthanasia
  - Ideally 100 mL
- Culture of lung tissue samples (quantitative)
  - Ideally 8 to 10 samples with a pre-specified tissue sampling plan
- Identification (MALDI-TOF)
- Antibiotic susceptibility testing



### **Proposed Euthanasia Criteria**

#### **Parameter**

- Technical
- Severe Hypoxia
- Mean Arterial Blood Pressure
- Electrocardiography

#### **Potential Humane Endpoint**

- Any adverse mechanical event that cannot be remedied
- < 40 mm of PaO<sub>2</sub> twice, 5 minutes apart with FiO<sub>2</sub> of 100%
- Persistent hypotension, < 30 mm Hg for > 30 minutes
- Asystole for > 3 minutes



## **Necropsy**

- Gross necropsy findings
- Sterile collection of tissues for bacteriology
- Collection of lung samples for histopathology
- Grading of pathologic lesions (Marquette, 1999)
- Collection of a limited set of tissues for histopathology



#### **Conclusions**

- Pilot studies demonstrate feasibility of mechanical ventilation for 96h in the Yorkshire-Landrace pigs
- Large animal model is amenable to physiologic and microbiologic characterization of the natural history of disease
- Large animal studies are challenging to establish and conduct



#### **How to Contact BARDA**









#### phe.gov/BARDA

Program description, information, news, announcements, connect to TechWatch

#### medicalcountermeasures.

gov

Portal to BARDA: Register to request a TechWatch meeting!

#### beta.sam.gov/

Official announcements and info for all government contract solicitations

#### drive.hhs.gov

Learn about DRIVe, including our Accelerator Network and FZ BAA



www.usajobs.gov

Join the team!

